Employees (Full-time equivalent)
CORE EBITDA in CHF
Sales in CHF
CORE EBITDA margin in %
ROIC in %
Sales growth in % 1
Global development and manufacturing sites
Nationalities
Brands
Active patent families
Trademark filings
Years of history
Small2 and large3 molecules
Constant exchange rate (CER); in actual exchange rate (AER) +20.0%.
Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering.
Including mammalian, microbial, bioconjugates and cell and gene therapy products (early development services, drug product services and personalized medicines are included for pre-clinical and clinical molecules only)
Million CHF
In %
Million CHF
In %
Million CHF
In %
CHF
Ratio
Reported pro-forma 2017 financial results (restated for IFRS 15) include Capsugel Full-Year 2017 financial result
Lonza continuing operations, excluding the Water Care business classified as discontinued operations
Lonza continuing operations, excluding the Specialty Ingredients business classified as discontinued operations
CORE results for the Full-Year 2020 were restated to reflect the changes from the revised Alternative Performance Measures policy that was introduced on 1 January 2021
“Net debt / CORE EBITDA” reflect total group including discontinued operations. In 2021, the net debt / CORE EBITDA ratio calculated on continuing operations only would result in a ratio of (0.58)
Lonza including Water Care business
| million CHF | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 1 | 2019 2 | 2020 2,3 | 2021 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,925 | 3,584 | 3,640 | 3,803 | 4,132 | 4,548 | 5,542 | 4,207 | 4,508 | 5,409 |
| CORE EBITDA | 663 | 711 | 743 | 793 | 918 | 1,196 | 1,511 | 1,334 | 1,379 | 1,665 |
| Margin in % | 16.9 | 19.8 | 20.4 | 20.9 | 22.2 | 26.5 | 27.3 | 31.7 | 30.6 | 30.8 |
| EBITDA | 645 | 647 | 737 | 780 | 848 | 1,084 | 1,429 | 1,264 | 1,378 | 1,365 |
| Margin in % | 16.4 | 18.1 | 20.2 | 20.5 | 20.5 | 23.8 | 25.8 | 30.0 | 30.6 | 25.2 |
| Result from operating activities (EBIT) | 340 | 253 | 423 | 428 | 486 | 673 | 842 | 825 | 901 | 851 |
| Margin in % | 8.7 | 7.1 | 11.6 | 11.3 | 11.8 | 14.8 | 15.2 | 19.6 | 20.0 | 15.7 |
| ROIC in % 4 | n.a. | n.a. | n.a. | n.a. | n.a. | 8.4 | 8.0 | 9.2 | 9.1 | 10.7 |
| CORE EPS (diluted) in CHF | 4.54 | 4.97 | 6.76 | 6.76 | 8.38 | 10.78 | 11.98 | 11.40 | 9.78 | 12.63 |
| EPS (diluted) in CHF | 3.35 | 1.67 | 4.54 | 5.26 | 5.69 | 9.70 | 8.77 | 8.68 | 9.77 | 9.05 |
| Operational free cash flow (bef. acquisitions) | 510 | 519 | 476 | 693 | 638 | 658 | 884 | 371 | 504 | 399 |
| Net debt / (net cash) 5 | 2,301 | 2,103 | 2,011 | 1,660 | 1,584 | 3,762 | 3,534 | 2,961 | 2,813 | (958) |
| Net debt / CORE EBITDA 5 | 3.47 | 2.96 | 2.70 | 2.09 | 1.73 | 2.70 | 2.28 | 1.83 | 1.66 | (0.53) |
| Number of employees (Full-Time Equivalent) 6 | 10,789 | 9,935 | 9,809 | 9,829 | 10,130 | 14,618 | 15,375 | 15,468 | 14,062 | 16,218 |
Lonza continuing operations, excluding the Water Care business classified as discontinued operations
Lonza continuing operations, excluding the Specialty Ingredients business classified as discontinued operations (see note 5.1 from Financial Statements PDF)
CORE results for the Full-Year 2020 (CORE EBITDA, ROIC, CORE EPS) were restated to reflect the changes from the revised Alternative Performance Measures policy that was introduced on 1 January 2021
Refer to section “Alternative Performance Measures” of the Financial Report for more details on the calculation methodology
“Net debt”, “Net debt / CORE EBITDA” reflect total group including discontinued operations. In 2021, the net debt / CORE EBITDA ratio calculated on continuing operations only would result in a ratio of (0.58)
“Number of employees (Full-time Equivalent)” reflect total group (including discontinued operations) from 2012 to 2019 and continuing operations (excluding Lonza Specialty Ingredients business) from 2020 onwards
